ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
Entera Bio presented Late-Breaking Phase 1 data at ENDO 2026 showing its single-tablet oral EB613 achieves pharmacokinetic and pharmacodynamic profiles comparable to Eli Lilly’s injectable Forteo. The study of 15 healthy participants demonstrated that the single-tablet regimen matches the efficacy of the multi-tablet version while offering superior patient preference, with 14 of 15 participants preferring the single tablet and all preferring oral administration over daily injections.
Key figures
- Drug Name
- EB613
- Phase Of Trial
- Phase 1
- Dose range mg
- 1-3
- Study participants
- 15
- Preference single tablet
- 14 of 15
- Preference oral vs injection
- 15 of 15
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.